Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced that the company will participate in two upcoming in-person investor conferences.
SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will participate in two upcoming in-person investor conferences:
- Thursday, June 9 at 1:00 p.m. ET / 10:00 a.m. PT at the Jefferies Healthcare Conference. Neha Krishnamohan, chief financial officer and executive vice president, corporate strategy, will represent the company in a fireside chat at the conference.
- Wednesday, June 15 at 1:00 p.m. ET / 10:00 a.m. PT at the Goldman Sachs 43rd Annual Global Healthcare Conference. Nima Farzan, chief executive officer, will represent the company in a fireside chat at the conference.
Members of the Kinnate management team will also host investor meetings during the conferences.
Investors and the general public are invited to listen to a live webcast of the session through the “Investors and Media” section on Kinnate.com. A webcast replay will be made available following the event for 30 days.
About Kinnate Biopharma Inc.
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products that are designed to address significant unmet need. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. For more information, visit Kinnate.com or follow us on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors as described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 that we have filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason in the future.
Investor & Media Contact:
Priyanka Shah | Priyanka.Shah@kinnate.com | +1-908-447-6134
